Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than...

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

Array (ARRY -14.8%) takes a pounding after its ARRY-797 drug failed to reduce pain better than an existing standard treatment, Oxycodone, in a Phase II trial of osteoarthritis patients. However, ARRY-797 did did meet its primary endpoints and reduced pain much more than a placebo. (PR)